Jennie H Best

Author PubWeight™ 8.33^‹?›

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.	Cancer	2005	1.00
2	Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.	J Med Econ	2012	0.94
3	Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.	Cardiovasc Diabetol	2013	0.84
4	Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs.	Curr Med Res Opin	2010	0.82
5	Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US.	J Med Econ	2012	0.81
6	Observational study of kidney function and albuminuria in patients with type 2 diabetes treated with exenatide BID versus insulin glargine.	Ann Pharmacother	2014	0.80
7	The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment.	J Med Econ	2010	0.80
8	Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States.	J Med Econ	2012	0.79
9	Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.	J Diabetes	2014	0.78
10	Development and validation of the self-management profile for type 2 diabetes (SMP-T2D).	Health Qual Life Outcomes	2012	0.75